About Us / Board of Directors
Macrogenics' Board of Directors
Expand all [+]
Paulo Costa
Former President & CEO, Novartis U.S. Corporation [-] Paulo Costa is the former President and Chief Executive Officer of Novartis U.S. Corporation. While at Novartis, he held a number of other roles including Head of the Americas, and President and Chief Executive Officer of Novartis Pharmaceuticals Corporation, Novartis' largest pharmaceutical business. He was responsible for the entire General Medicine business in North and Latin America. Under Mr. Costa’s leadership, the pharmaceutical business achieved compounded annual double-digit growth and gained substantial market share. Prior to joining Novartis, Mr. Costa worked at Johnson & Johnson for 30 years, where he served as President of Janssen Pharmaceutica, Executive Vice President, Global Franchise Development, and was a member of Johnson & Johnson's Group Operating Committee. Mr. Costa has held various sales and marketing positions and has more than 20 years of general management experience, having launched over 10 pharmaceutical products in various therapeutic areas in the U.S. market.
Mr. Costa is a Director of Amylin Pharmaceuticals, Inc. Mr. Costa earned his M.B.A. from Harvard Business School and is a graduate of the Sao Paulo School of Business Administration. Ken Galbraith [A]
General Partner, Ventures West Management Ltd. [-] Ken Galbraith joined Ventures West in 2007 and leads the firm's biotech practice. Mr. Galbraith is a well-known and active member of the North American life sciences community with over 20 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. In 2006, Mr. Galbraith served as the Chairman and Interim CEO of AnorMED, a biopharmaceutical company focused on new therapeutic products in hematology, HIV and oncology, until its sale to Genzyme Corp. in a cash transaction worth almost $600 million. Previously, Mr. Galbraith spent 13 years in senior management with QLT Inc., a global biopharmaceutical company specializing in developing treatments for eye diseases and oncology, retiring in 2000 from his position as Executive VP and CFO. QLT is best known for its product Visudyne, used for the treatment of age-related macular degeneration (AMD) in more than 75 countries around the world, with peak sales in 2005 of approximately $500 million. Mr. Galbraith was a founding Director of the BC Biotechnology Alliance and served as Chairman of the Canadian Bacterial Diseases Network, one of Canada's federally-funded Networks for Centers of Excellence (NCE). He was also a Director of the Michael Smith Foundation for Health Research and the Fraser Health Authority. He currently serves on the Board of Directors of the Vancouver Aquarium Marine Science Centre, one of the world's leading aquariums and Genome BC. Mr. Galbraith has served on the Board of Directors of several public and private biotechnology companies located in BC and the US, including Angiotech Pharmaceuticals and Cardiome Pharma. He currently serves as a Director of Alder Biopharmaceuticals, Aquinox Pharmaceuticals, Celator Pharmaceuticals, NeurAxon and Presidio Pharmaceuticals.
Mr. Galbraith earned a Bachelor of Commerce (Honours) degree from the University of British Columbia and is a Chartered Accountant. Edward Hurwitz [A,C]
General Partner, Alta Partners [-] Edward Hurwitz is a General Partner at Alta Partners, which he joined in 2002. Prior to joining Alta, he was Senior Vice President and Chief Financial Officer of Affymetrix from 1997 to 2002. Prior to that, he served as a Biotechnology Research Analyst for Robertson Stephens & Company from 1994 to 1997 and Smith Barney Shearson from 1992 to 1994. Mr. Hurwitz also practiced commercial law at Cooley Godward L.L.P. from 1990 to 1992. He serves on the Board of Directors of Avid Radiopharmaceuticals, Calistoga Pharmaceuticals, Cara Therapeutics, FoldRx Pharmaceuticals, Sunesis and Taligen Therapeutics.
Mr. Hurwitz received a Juris Doctor from the University of California at Berkeley's Boalt School of Law and earned an M.B.A. degree in 1990 from the Haas School of Business. Mr. Hurwitz also received a Bachelor of Arts in Molecular Biology from Cornell University in 1985. Scott Koenig, M. D., Ph. D.
President and CEO, MacroGenics [-] Scott Koenig has been President and Chief Executive Officer of MacroGenics since September 2001. Prior to joining MacroGenics, he served as Senior Vice President of Research at MedImmune Inc., where he participated in the selection and maturation of the company's product pipeline for 11 years. From 1984 to 1990, Dr. Koenig worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Currently, he is Chairman of the Board of Directors at Applied Genetic Therapy Corporation, a private venture-backed biotechnology company developing genetic therapies using adeno-associated virus vectors. Dr. Koenig is a Board member of BIO, as well as a member of its Emerging Companies Section Governing Body. Dr. Koenig is also a Board member of the Children's Research Institute at the Children's National Medical Center.
Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston, where he was elected to Alpha Omega Alpha. He completed his residency in Internal Medicine at the Hospital of the University of Pennsylvania and is Board certified in Internal Medicine and Allergy and Immunology. Arnold Oronsky, Ph.D.[A]
General Partner, InterWest Partners [-] Arnold Oronsky is a General Partner at InterWest Partners, a venture capital firm focusing on investments in life sciences and information technology. Dr. Oronsky joined InterWest Partners in a full-time capacity in 1994 after serving as a special limited partner since 1989. He also serves as a senior lecturer in the Department of Medicine at Johns Hopkins Medical School. From 1980 to 1993, Dr. Oronsky was Vice President for Discovery Research at the Lederle Laboratories division of American Cynamid Company, a pharmaceutical company. From 1973 to 1976, Dr. Oronsky was Head of Inflammation, Allergy and Immunology Research at Ciba-Geigy. From 1970 to 1972, he was an assistant professor at Harvard Medical School, where he also served as a research fellow from 1968 to 1970. Dr. Oronsky has won numerous grants and awards and has published over 125 scientific articles. Dr. Oronsky serves on the boards of directors of Dynavax Technologies, Metabasis Therapeutics and Anesiva.
Dr. Oronsky received his Ph.D. from Columbia University, College of Physicians and Surgeons and his A.B. from New York University. Paul Sekhri
Head - Biotech Ops Group, TPG Biotech[-]
Managing Director, Clarus Ventures, LLC [-] Michael Steinmetz has been Managing Director of Clarus Ventures since the firm’s inception in 2005. He has over 24 years of direct industry and investment experience within the healthcare sector, including being a General Partner in a healthcare venture capital firm since 1997. From 1986 to 1997, Dr. Steinmetz was an executive at Hoffmann-LaRoche where he held various positions including Vice President of Preclinical Research and Development, and Global Head of Biotechnology. Dr. Steinmetz represents Clarus Ventures on the Board of Directors of ESBATech, Oxford Immunotec, and Virdante. In addition, he is a member of the Board of Directors of Allozyne, Biovitrum, CGI Pharmaceuticals, TaiGen, and VLST Corp.
Dr. Steinmetz obtained his Ph.D. summa cum laude from the University of Munich and held positions at the California Institute of Technology and the Basel Institute for Immunology.
[A] = Member of Audit Committee
[C] = Member of Compensation Committee
Former President & CEO, Novartis U.S. Corporation [-] Paulo Costa is the former President and Chief Executive Officer of Novartis U.S. Corporation. While at Novartis, he held a number of other roles including Head of the Americas, and President and Chief Executive Officer of Novartis Pharmaceuticals Corporation, Novartis' largest pharmaceutical business. He was responsible for the entire General Medicine business in North and Latin America. Under Mr. Costa’s leadership, the pharmaceutical business achieved compounded annual double-digit growth and gained substantial market share. Prior to joining Novartis, Mr. Costa worked at Johnson & Johnson for 30 years, where he served as President of Janssen Pharmaceutica, Executive Vice President, Global Franchise Development, and was a member of Johnson & Johnson's Group Operating Committee. Mr. Costa has held various sales and marketing positions and has more than 20 years of general management experience, having launched over 10 pharmaceutical products in various therapeutic areas in the U.S. market.
Mr. Costa is a Director of Amylin Pharmaceuticals, Inc. Mr. Costa earned his M.B.A. from Harvard Business School and is a graduate of the Sao Paulo School of Business Administration. Ken Galbraith [A]
General Partner, Ventures West Management Ltd. [-] Ken Galbraith joined Ventures West in 2007 and leads the firm's biotech practice. Mr. Galbraith is a well-known and active member of the North American life sciences community with over 20 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. In 2006, Mr. Galbraith served as the Chairman and Interim CEO of AnorMED, a biopharmaceutical company focused on new therapeutic products in hematology, HIV and oncology, until its sale to Genzyme Corp. in a cash transaction worth almost $600 million. Previously, Mr. Galbraith spent 13 years in senior management with QLT Inc., a global biopharmaceutical company specializing in developing treatments for eye diseases and oncology, retiring in 2000 from his position as Executive VP and CFO. QLT is best known for its product Visudyne, used for the treatment of age-related macular degeneration (AMD) in more than 75 countries around the world, with peak sales in 2005 of approximately $500 million. Mr. Galbraith was a founding Director of the BC Biotechnology Alliance and served as Chairman of the Canadian Bacterial Diseases Network, one of Canada's federally-funded Networks for Centers of Excellence (NCE). He was also a Director of the Michael Smith Foundation for Health Research and the Fraser Health Authority. He currently serves on the Board of Directors of the Vancouver Aquarium Marine Science Centre, one of the world's leading aquariums and Genome BC. Mr. Galbraith has served on the Board of Directors of several public and private biotechnology companies located in BC and the US, including Angiotech Pharmaceuticals and Cardiome Pharma. He currently serves as a Director of Alder Biopharmaceuticals, Aquinox Pharmaceuticals, Celator Pharmaceuticals, NeurAxon and Presidio Pharmaceuticals.
Mr. Galbraith earned a Bachelor of Commerce (Honours) degree from the University of British Columbia and is a Chartered Accountant. Edward Hurwitz [A,C]
General Partner, Alta Partners [-] Edward Hurwitz is a General Partner at Alta Partners, which he joined in 2002. Prior to joining Alta, he was Senior Vice President and Chief Financial Officer of Affymetrix from 1997 to 2002. Prior to that, he served as a Biotechnology Research Analyst for Robertson Stephens & Company from 1994 to 1997 and Smith Barney Shearson from 1992 to 1994. Mr. Hurwitz also practiced commercial law at Cooley Godward L.L.P. from 1990 to 1992. He serves on the Board of Directors of Avid Radiopharmaceuticals, Calistoga Pharmaceuticals, Cara Therapeutics, FoldRx Pharmaceuticals, Sunesis and Taligen Therapeutics.
Mr. Hurwitz received a Juris Doctor from the University of California at Berkeley's Boalt School of Law and earned an M.B.A. degree in 1990 from the Haas School of Business. Mr. Hurwitz also received a Bachelor of Arts in Molecular Biology from Cornell University in 1985. Scott Koenig, M. D., Ph. D.
President and CEO, MacroGenics [-] Scott Koenig has been President and Chief Executive Officer of MacroGenics since September 2001. Prior to joining MacroGenics, he served as Senior Vice President of Research at MedImmune Inc., where he participated in the selection and maturation of the company's product pipeline for 11 years. From 1984 to 1990, Dr. Koenig worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Currently, he is Chairman of the Board of Directors at Applied Genetic Therapy Corporation, a private venture-backed biotechnology company developing genetic therapies using adeno-associated virus vectors. Dr. Koenig is a Board member of BIO, as well as a member of its Emerging Companies Section Governing Body. Dr. Koenig is also a Board member of the Children's Research Institute at the Children's National Medical Center.
Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston, where he was elected to Alpha Omega Alpha. He completed his residency in Internal Medicine at the Hospital of the University of Pennsylvania and is Board certified in Internal Medicine and Allergy and Immunology. Arnold Oronsky, Ph.D.[A]
General Partner, InterWest Partners [-] Arnold Oronsky is a General Partner at InterWest Partners, a venture capital firm focusing on investments in life sciences and information technology. Dr. Oronsky joined InterWest Partners in a full-time capacity in 1994 after serving as a special limited partner since 1989. He also serves as a senior lecturer in the Department of Medicine at Johns Hopkins Medical School. From 1980 to 1993, Dr. Oronsky was Vice President for Discovery Research at the Lederle Laboratories division of American Cynamid Company, a pharmaceutical company. From 1973 to 1976, Dr. Oronsky was Head of Inflammation, Allergy and Immunology Research at Ciba-Geigy. From 1970 to 1972, he was an assistant professor at Harvard Medical School, where he also served as a research fellow from 1968 to 1970. Dr. Oronsky has won numerous grants and awards and has published over 125 scientific articles. Dr. Oronsky serves on the boards of directors of Dynavax Technologies, Metabasis Therapeutics and Anesiva.
Dr. Oronsky received his Ph.D. from Columbia University, College of Physicians and Surgeons and his A.B. from New York University. Paul Sekhri
Head - Biotech Ops Group, TPG Biotech[-]
Prior to joining TPG Biotech in January 2009 as Head, Biotech Ops Group, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. In 2002, Mr. Sekhri joined the Sprout Group, the venture affiliate of Credit Suisse First Boston in New York, where he was a Partner for healthcare technology investments.
Prior to joining Sprout, Mr. Sekhri spent four years at Novartis, most recently as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Prior to this, Mr. Sekhri developed the Disease Area Strategy for Novartis, identifying those specific therapeutic areas upon which the company would focus. His first role at Novartis was as Global Head, Early Commercial Development - a department he established to ensure the differential competitive advantage of Novartis' pipeline.
Mr. Sekhri completed graduate work in neuroscience at the University of Maryland School of Medicine where he also received his BS in Zoology.
Mr. Sekhri has been a Director on more than ten private and public company Boards, and is currently a member of the Board of Directors of Affectis Pharmaceuticals, APT Pharmaceuticals, ARYx Therapeutics, KAI Pharmaceuticals, Intercept Pharmaceuticals and is a Board Observer at Moksha8 and IMS Health.
Additionally, he is on the Board of Directors of the non-profit Cancer Research Institute and the BioExec Institute, Inc. Mr. Sekhri is also an Advisor to the Brookings Global Health Financing Initiative, is an LES M&A Committee member, a member of the Ontario Institute for Cancer Research (OICR) Commercialization Advisory Committee, and was recently elected to the Board of Trustees of Carnegie Hall.
Michael Steinmetz, Ph.D.[C]Mr. Sekhri completed graduate work in neuroscience at the University of Maryland School of Medicine where he also received his BS in Zoology.
Mr. Sekhri has been a Director on more than ten private and public company Boards, and is currently a member of the Board of Directors of Affectis Pharmaceuticals, APT Pharmaceuticals, ARYx Therapeutics, KAI Pharmaceuticals, Intercept Pharmaceuticals and is a Board Observer at Moksha8 and IMS Health.
Additionally, he is on the Board of Directors of the non-profit Cancer Research Institute and the BioExec Institute, Inc. Mr. Sekhri is also an Advisor to the Brookings Global Health Financing Initiative, is an LES M&A Committee member, a member of the Ontario Institute for Cancer Research (OICR) Commercialization Advisory Committee, and was recently elected to the Board of Trustees of Carnegie Hall.
Managing Director, Clarus Ventures, LLC [-] Michael Steinmetz has been Managing Director of Clarus Ventures since the firm’s inception in 2005. He has over 24 years of direct industry and investment experience within the healthcare sector, including being a General Partner in a healthcare venture capital firm since 1997. From 1986 to 1997, Dr. Steinmetz was an executive at Hoffmann-LaRoche where he held various positions including Vice President of Preclinical Research and Development, and Global Head of Biotechnology. Dr. Steinmetz represents Clarus Ventures on the Board of Directors of ESBATech, Oxford Immunotec, and Virdante. In addition, he is a member of the Board of Directors of Allozyne, Biovitrum, CGI Pharmaceuticals, TaiGen, and VLST Corp.
Dr. Steinmetz obtained his Ph.D. summa cum laude from the University of Munich and held positions at the California Institute of Technology and the Basel Institute for Immunology.
[A] = Member of Audit Committee
[C] = Member of Compensation Committee
Partnering
MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.
Learn more